📊 NBY Key Takeaways
Is NovaBay Pharmaceuticals, Inc. (NBY) a Good Investment?
Stablecoin Development Corp exhibits terminal financial distress with negative stockholders' equity of -$23.2M, indicating technical insolvency. The company is burning $8.4M annually in operating losses against only $521K in declining revenue, creating a fundamentally unsustainable business model that will exhaust its $8M cash reserve within 12 months absent significant operational transformation or external capital injection.
Fundamentals are severely impaired: minimal revenue with single‑digit gross margin and extremely negative operating and net margins indicate an unsustainable model. Negative shareholders’ equity and sizable operating cash burn relative to cash on hand point to acute solvency and financing risk. Without clear evidence of material revenue inflection or cost restructuring, the business trajectory remains highly unfavorable.
Why Buy NovaBay Pharmaceuticals, Inc. Stock? NBY Key Strengths
- Maintains $8.0M cash reserve providing short-term liquidity buffer
- Minimal capital expenditure requirements ($0) reduces ongoing investment needs
- Recent insider activity suggests management engagement despite distress
- High current and quick ratios provide short‑term liquidity
- Cash on hand offers limited but immediate runway
- Asset‑light model with negligible capex requirements
NBY Stock Risks: NovaBay Pharmaceuticals, Inc. Investment Risks
- Negative stockholders' equity of -$23.2M represents technical insolvency with liabilities exceeding assets by $22.9M
- Operating cash burn of -$8.4M annually against $521K revenue is mathematically unsustainable; cash runway approximately 12 months
- Gross margin of 8.1% indicates severe operational inefficiency; unit economics appear broken
- Revenue declining 6.4% YoY demonstrates deteriorating market traction or demand
- Massive net losses (-$22.1M) and operating losses (-$8.4M) on minimal revenue base signal fundamental business model failure
- EPS improvement amid revenue decline and increased losses suggests dilutive capital raises likely
- Persistent operating losses and heavy cash burn
- Negative shareholders’ equity signaling solvency risk and potential restructuring
- Declining revenue and very low gross margin limiting path to breakeven
Key Metrics to Watch
- Cash burn rate and remaining cash runway (critical near-term solvency indicator)
- Revenue stabilization and gross margin improvement (currently unsustainable)
- Restructuring or capital raise announcements (required for survival)
- Change in total liabilities and stockholders' equity trajectory (insolvency indicator)
- Quarterly operating cash burn vs. cash runway
- Revenue growth and gross margin improvement
NovaBay Pharmaceuticals, Inc. (NBY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.60x current ratio provides a solid financial cushion.
NBY Profit Margin, ROE & Profitability Analysis
NBY vs Healthcare Sector: How NovaBay Pharmaceuticals, Inc. Compares
How NovaBay Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NovaBay Pharmaceuticals, Inc. Stock Overvalued? NBY Valuation Analysis 2026
Based on fundamental analysis, NovaBay Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NovaBay Pharmaceuticals, Inc. Balance Sheet: NBY Debt, Cash & Liquidity
NBY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NovaBay Pharmaceuticals, Inc.'s revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-12.68 indicates the company is currently unprofitable.
NBY Revenue Growth, EPS Growth & YoY Performance
NBY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.2M | $-0.22 |
| Q3 2024 | $2.4M | -$1.2M | N/A |
| Q2 2024 | $2.4M | -$1.6M | N/A |
| Q1 2024 | $2.3M | -$1.7M | N/A |
| Q3 2023 | $3.3M | -$111.0K | N/A |
| Q2 2023 | $3.7M | -$111.0K | N/A |
| Q1 2023 | $3.1M | -$111.0K | N/A |
| Q3 2022 | $2.3M | -$111.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NovaBay Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
NBY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NovaBay Pharmaceuticals, Inc. (CIK: 0001389545)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NBY
What is the AI rating for NBY?
NovaBay Pharmaceuticals, Inc. (NBY) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NBY's key strengths?
Claude: Maintains $8.0M cash reserve providing short-term liquidity buffer. Minimal capital expenditure requirements ($0) reduces ongoing investment needs. ChatGPT: High current and quick ratios provide short‑term liquidity. Cash on hand offers limited but immediate runway.
What are the risks of investing in NBY?
Claude: Negative stockholders' equity of -$23.2M represents technical insolvency with liabilities exceeding assets by $22.9M. Operating cash burn of -$8.4M annually against $521K revenue is mathematically unsustainable; cash runway approximately 12 months. ChatGPT: Persistent operating losses and heavy cash burn. Negative shareholders’ equity signaling solvency risk and potential restructuring.
What is NBY's revenue and growth?
NovaBay Pharmaceuticals, Inc. reported revenue of $521.0K.
Does NBY pay dividends?
NovaBay Pharmaceuticals, Inc. pays dividends, with $4.8M distributed to shareholders in the trailing twelve months.
Where can I find NBY SEC filings?
Official SEC filings for NovaBay Pharmaceuticals, Inc. (CIK: 0001389545) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NBY's EPS?
NovaBay Pharmaceuticals, Inc. has a diluted EPS of $0.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NBY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NovaBay Pharmaceuticals, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NBY stock overvalued or undervalued?
Valuation metrics for NBY: ROE of N/A (sector avg: 15%), net margin of -4,249.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NBY stock in 2026?
Our dual AI analysis gives NovaBay Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NBY's free cash flow?
NovaBay Pharmaceuticals, Inc.'s operating cash flow is $-8.4M, with capital expenditures of $0.0. FCF margin is -1,618.0%.
How does NBY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,249.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 7.60 (avg: 2).